ARQT — Arcutis Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $3.66bn
- $3.53bn
- $376.07m
Brief: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Arcutis Submits SNDA For Zoryve Cream For Treatment Of Plaque Psoriasis In Children
Brief: Palvella Therapeutics Strengthens Leadership With Appointment Of Accomplished Scientist And Biopharmaceutical Executive David W. Osborne, Ph.D. As Chief Innovation Officer
Brief: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Arcutis Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Arcutis Technologies Q2 product revenue surges
Brief: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Arcutis Enrolls First Child In INTEGUMENT-INFANT Evaluating ZORYVE Cream 0.05% In Infants With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule
Arcutis Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Arcutis Announces Chief Financial Officer Transition
Brief: Arcutis And Padagis Agree To Stay Patent Lawsuit
Arcutis rises after halting patent dispute with Padagis
U.S. STOCKS ON THE MOVE-AerCap Holdings, Salesforce, Emcor Group
U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences
Arcutis Biotherapeutics rises on strong sales of skin disease drug
Arcutis Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. RESEARCH ROUNDUP-CNX Resources, Inari Medical, Royal Gold
Brief: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)